<DOC>
	<DOC>NCT02141282</DOC>
	<brief_summary>This is an open-label, non-randomized, multicenter, Phase 2 study evaluating the efficacy and safety of ABT-199 in approximately 120 subjects with relapsed or refractory CLL after B-cell receptor signaling pathway inhibitors (BCR PI) treatment.</brief_summary>
	<brief_title>A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<mesh_term>Idelalisib</mesh_term>
	<mesh_term>Receptors, Antigen, B-Cell</mesh_term>
	<criteria>Subject must have a diagnosis of CLL that meets 2008 Modified International Workshop on Chronic Lymphocytic Leukemia National Cancer InstituteWorking Group (iwCLL NCIWG) criteria Subject has relapsed/refractory disease with an indication for treatment Subject has refractory disease or developed recurrence after therapy with a BCR PI Subject must have an Eastern Cooperative Oncology Group performance score of equal to or less than 2 Subject must have adequate bone marrow function at Screening Subject must have adequate coagulation profile, renal, and hepatic function, per laboratory reference range at Screening Subject has undergone an allogeneic stem cell transplant within the past year Subject has developed Richter's transformation confirmed by biopsy Subject has active and uncontrolled autoimmune cytopenia Subject has malabsorption syndrome or other condition that precludes enteral route of administration Subject is human immunodeficiency virus (HIV) positive or has chronic hepatitis B or hepatitis C virus requiring treatment Subject has known contraindication or allergy to both xanthine oxidase inhibitors and rasburicase.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Oncology</keyword>
	<keyword>Cancer of the blood and bone marrow</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
</DOC>